Fevipiprant is superior to montelukast in suppressing type 2 cytokine production from mast cell stimulated human Th2 cells

S. Kazani (Cambridge, United States of America), F. Hasler (Basel, Switzerland), P. Jaeger (Basel, Switzerland), C. Maurer (Basel, Switzerland), D. Sandham (Cambridge, United States of America), T. Roehn (Basel, Switzerland)

Source: International Congress 2019 – Precision meets immunology in treatment of airway diseases
Session: Precision meets immunology in treatment of airway diseases
Session type: Oral Presentation
Number: 3808

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Kazani (Cambridge, United States of America), F. Hasler (Basel, Switzerland), P. Jaeger (Basel, Switzerland), C. Maurer (Basel, Switzerland), D. Sandham (Cambridge, United States of America), T. Roehn (Basel, Switzerland). Fevipiprant is superior to montelukast in suppressing type 2 cytokine production from mast cell stimulated human Th2 cells. 3808

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: